DK3571225T3 - Forbedrede serumalbuminbindere - Google Patents

Forbedrede serumalbuminbindere Download PDF

Info

Publication number: DK3571225T3
Authority: DK; Denmark
Prior art keywords: serum albumin; improved serum; albumin binders; binders; improved
Prior art date: 2017-01-17

Application number

DK18707848.0T

Other languages

English (en)

Inventor

Stephanie Staelens

Soren Steffensen

An Cerdobbel

Erika Morizzo

Original Assignee

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-01-17

Filing date

2018-01-17

Publication date

2024-11-04

2018-01-17 Application filed by Ablynx Nv filed Critical Ablynx Nv

2024-11-04 Application granted granted Critical

2024-11-04 Publication of DK3571225T3 publication Critical patent/DK3571225T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK18707848.0T 2017-01-17 2018-01-17 Forbedrede serumalbuminbindere DK3571225T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762446988P	2017-01-17	2017-01-17
PCT/EP2018/051083 WO2018134235A1 (en)	2017-01-17	2018-01-17	Improved serum albumin binders

Publications (1)

Publication Number	Publication Date
DK3571225T3 true DK3571225T3 (da)	2024-11-04

Family

ID=61521465

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18707848.0T DK3571225T3 (da)	2017-01-17	2018-01-17	Forbedrede serumalbuminbindere

Country Status (21)

Country	Link
US (1)	US11414481B2 (da)
EP (3)	EP3571225B1 (da)
JP (3)	JP7219220B2 (da)
KR (2)	KR102662499B1 (da)
CN (2)	CN117285623A (da)
AU (2)	AU2018209151B2 (da)
BR (1)	BR112019014599A2 (da)
CA (1)	CA3050575A1 (da)
DK (1)	DK3571225T3 (da)
ES (1)	ES2991459T3 (da)
FI (1)	FI3571225T3 (da)
HR (1)	HRP20241469T1 (da)
HU (1)	HUE068790T2 (da)
IL (2)	IL267894B2 (da)
LT (1)	LT3571225T (da)
MX (2)	MX2019008496A (da)
PT (1)	PT3571225T (da)
RS (1)	RS66117B1 (da)
SG (2)	SG11201906264YA (da)
SI (1)	SI3571225T1 (da)
WO (1)	WO2018134235A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
HUE031828T2 (en)	2011-06-23	2017-08-28	Ablynx Nv	Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
EP3551656A1 (en)	2016-12-07	2019-10-16	Ablynx NV	Improved serum albumin binding immunoglobulin single variable domains
DK3571224T3 (da)	2017-01-17	2024-11-11	Ablynx Nv	Forbedrede serumalbuminbindere
CN117285623A (zh) *	2017-01-17	2023-12-26	埃博灵克斯股份有限公司	改进的血清白蛋白结合物
JP7657797B2 (ja)	2019-12-06	2025-04-07	アブリンクスエン．ヴェー．	ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
MX2022006881A (es)	2019-12-06	2022-07-11	Ablynx Nv	Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
IL293548A (en)	2019-12-09	2022-08-01	Ablynx Nv	Polypeptides comprising immunoglobulin with single variable domains targeting 13 il and tsl
WO2021140205A1 (en)	2020-01-10	2021-07-15	Confo Therapeutics N.V.	Methods for generating antibodies and antibody fragments and libraries comprising same
CA3175873A1 (en)	2020-03-30	2021-10-07	Ablynx Nv	Method for the production and purification of multivalent immunoglobulin single variable domains
WO2024133935A1 (en)	2022-12-23	2024-06-27	Ablynx Nv	Protein-based conjugation carriers
WO2022063984A1 (en)	2020-09-25	2022-03-31	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
JP7842101B2 (ja)	2020-12-18	2026-04-07	アブリンクスエン．ヴェー．	ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
TW202241947A (zh)	2020-12-18	2022-11-01	比利時商艾伯霖克斯公司	包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽
CA3203141A1 (en)	2020-12-18	2022-06-23	Ablynx Nv	T cell recruiting polypeptides based on tcr alpha/beta reactivity
AU2022409733A1 (en)	2021-12-17	2024-08-01	Ablynx Nv	POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
CA3259417A1 (en)	2022-06-14	2023-12-21	Ablynx Nv	UNIQUE VARIABLE DOMAINS OF IMMUNOGLOBULIN TARGETING THE T LYMPHOCYTE RECEPTOR
KR20250042176A (ko)	2022-07-27	2025-03-26	아블린쓰	신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드
WO2024084203A1 (en)	2022-10-18	2024-04-25	Isogenica Limited	Single domain antibodies binding to albumin
CN120529914A (zh)	2023-01-09	2025-08-22	奥德赛治疗股份有限公司	抗tnfr2抗原结合蛋白及其用途
AR131869A1 (es)	2023-02-17	2025-05-07	Ablynx Nv	POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
IL323035A (en)	2023-03-14	2025-10-01	Odyssey Therapeutics Inc	Anti-CD25 antigen-binding proteins and their uses
CN121511255A (zh)	2023-05-17	2026-02-10	奥德赛治疗股份有限公司	经修饰的单结构域抗体
KR102822958B1 (ko) *	2023-05-23	2025-06-20	대한민국(해양경찰청 해양경찰연구센터장)	고래 불법포획 감식용 신속진단키트
EP4731770A1 (en)	2023-06-22	2026-04-29	Ablynx NV	Chimeric proteins for modulating cytokine receptor activity
KR20260032566A (ko)	2023-06-29	2026-03-09	오디세이 테라퓨틱스, 인코포레이티드	항-trailr2 항원-결합 단백질 및 그의 용도
CN121443644A (zh)	2023-07-05	2026-01-30	阿布林克斯有限公司	用于治疗IgG相关疾病和障碍的改善的FcRn拮抗剂
AR133725A1 (es)	2023-09-04	2025-10-29	Sanofi Sa	Polipéptidos para uso en el tratamiento de tumores que expresan glipicano-3
CN121986112A (zh)	2023-09-22	2026-05-05	阿布林克斯有限公司	二价和多价白蛋白结合剂
WO2025080751A2 (en)	2023-10-13	2025-04-17	Odyssey Therapeutics, Inc.	Anti-cdh17 antigen-binding proteins and uses thereof
WO2025099632A1 (en)	2023-11-08	2025-05-15	Sanofi	Cd25 based lysosomal degrader and uses thereof
AR134512A1 (es)	2023-12-01	2026-01-21	Ablynx Nv	Polipéptidos activados con precisión
TW202543670A (zh)	2023-12-22	2025-11-16	比利時商艾伯霖克斯公司	用於核內投予之基於蛋白質的接合載劑
AR134804A1 (es)	2023-12-22	2026-04-01	Ablynx Nv	Portadores a base de proteínas para la conjugación de aminas específicas de sitio
TW202602941A (zh)	2024-04-10	2026-01-16	美商奧迪希治療公司	抗tnfr2抗原結合蛋白及其用途
WO2025217497A1 (en)	2024-04-12	2025-10-16	Paragon Therapeutics, Inc.	Albumin binding proteins and methods of use
TW202547857A (zh) *	2024-04-12	2025-12-16	美商派拉岡醫療公司	抗ｈａｓ抗體及其組合物
WO2025255558A2 (en)	2024-06-07	2025-12-11	Odyssey Therapeutics, Inc.	Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en)	2024-06-07	2025-12-11	Odyssey Therapeutics, Inc.	Antigen-binding proteins against serum albumin and uses thereof
WO2026006708A2 (en)	2024-06-27	2026-01-02	Odyssey Therapeutics, Inc.	Anti-cd25 antigen-binding proteins and uses thereof
WO2026030375A2 (en)	2024-07-30	2026-02-05	Genzyme Corporation	Lipid nanoparticles and methods of manufacture and use thereof
WO2026052756A1 (en)	2024-09-05	2026-03-12	Ablynx Nv	Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
WO2026078159A1 (en)	2024-10-10	2026-04-16	Ablynx Nv	Immune cell engagers and methods comprising the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1999023221A2 (en)	1997-10-27	1999-05-14	Unilever Plc	Multivalent antigen-binding proteins
US6742038B2 (en)	2000-04-07	2004-05-25	Danger, Inc.	System and method of linking user identification to a subscriber identification module
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1600459A3 (en)	2002-06-28	2005-12-07	Domantis Limited	Ligand
US9321832B2 (en) *	2002-06-28	2016-04-26	Domantis Limited	Ligand
EP2284192A3 (en)	2002-11-08	2011-07-20	Ablynx N.V.	Camelidae antibodies for sublingual administration
CA2588892A1 (en)	2004-12-02	2006-06-08	Dormantis Limited	Anti-il-1r1 single domain antibodies and therapeutic uses
AU2006249144B2 (en)	2005-05-18	2011-11-17	Ablynx Nv	Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es)	2005-05-20	2008-02-07	Ablynx Nv	Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
CN101454344A (zh)	2005-12-01	2009-06-10	杜门蒂斯有限公司	与白细胞介素-1受体1型结合的非竞争性域抗体形式
KR20080077237A (ko)	2005-12-01	2008-08-21	도만티스 리미티드	인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷
FR2894741B1 (fr)	2005-12-08	2009-12-04	Centre Nat Etd Spatiales	Chaine de reception par satellite
WO2007085814A1 (en)	2006-01-24	2007-08-02	Domantis Limited	Fusion proteins that contain natural junctions
CA2666599A1 (en)	2006-08-18	2008-02-21	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101646689A (zh) *	2006-09-08	2010-02-10	埃博灵克斯股份有限公司	具有长半衰期的血清清蛋白结合蛋白
KR101264473B1 (ko)	2007-05-24	2013-05-29	아블린쓰 엔.브이.	Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
WO2009068631A1 (en)	2007-11-27	2009-06-04	Ablynx N.V.	Method for obtaining polypeptide constructs comprising two or more single domain antibodies
DE102008023620A1 (de)	2008-05-15	2009-11-19	Mettler-Toledo (Albstadt) Gmbh	Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
NZ589036A (en)	2008-05-16	2012-07-27	Ablynx Nv	AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2010035012A1 (en)	2008-09-26	2010-04-01	Ucb Pharma S.A.	Biological products
WO2010130832A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EP2454285A2 (en)	2009-07-16	2012-05-23	Glaxo Group Limited	Improved anti-serum albumin binding single variable domains
SG10201406063XA (en)	2009-09-30	2014-11-27	Glaxo Group Ltd	Drug fusions and conjugates with extended half life
US9012609B2 (en)	2010-08-13	2015-04-21	Glaxosmithkline Intellectual Property Development Limited	Anti-serum albumin binding variants
SG188204A1 (en)	2010-08-20	2013-04-30	Glaxo Group Ltd	Improved anti-serum albumin binding variants
US11644471B2 (en) *	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
HUE031828T2 (en) *	2011-06-23	2017-08-28	Ablynx Nv	Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
EP2944654A1 (en) *	2011-06-23	2015-11-18	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EP3466972B1 (en)	2011-06-23	2026-03-04	Ablynx NV	Serum albumin binding proteins
US20150344568A1 (en) *	2011-06-23	2015-12-03	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012174741A1 (en)	2011-06-24	2012-12-27	Google Inc.	Determining cross-language query suggestion based on query translations
PE20141522A1 (es)	2011-08-17	2014-11-17	Glaxo Group Ltd	Proteinas y peptidos modificados
US20130129727A1 (en)	2011-11-17	2013-05-23	Nanjingjinsirui Science & Technology Biology Corporation	Methods and systems for increasing protein stability
WO2014037419A1 (en)	2012-09-04	2014-03-13	Vib Vzw	Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en) *	2013-01-03	2014-07-03	Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center	Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
SG11201609162SA (en)	2014-05-16	2016-12-29	Ablynx Nv	Improved immunoglobulin variable domains
JP7001474B2 (ja)	2015-01-21	2022-01-19	インヒブルクス，インコーポレイティド	非免疫原性単一ドメイン抗体
PT3294768T (pt)	2015-05-13	2019-11-05	Ablynx Nv	Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta
CN108473561B (zh)	2015-11-27	2022-12-16	埃博灵克斯股份有限公司	抑制cd40l的多肽
EP3551656A1 (en)	2016-12-07	2019-10-16	Ablynx NV	Improved serum albumin binding immunoglobulin single variable domains
CN117285623A (zh)	2017-01-17	2023-12-26	埃博灵克斯股份有限公司	改进的血清白蛋白结合物
DK3571224T3 (da) *	2017-01-17	2024-11-11	Ablynx Nv	Forbedrede serumalbuminbindere

2018
- 2018-01-17 CN CN202311123454.3A patent/CN117285623A/zh active Pending
- 2018-01-17 ES ES18707848T patent/ES2991459T3/es active Active
- 2018-01-17 JP JP2019538382A patent/JP7219220B2/ja active Active
- 2018-01-17 KR KR1020197024113A patent/KR102662499B1/ko active Active
- 2018-01-17 SG SG11201906264YA patent/SG11201906264YA/en unknown
- 2018-01-17 WO PCT/EP2018/051083 patent/WO2018134235A1/en not_active Ceased
- 2018-01-17 RS RS20241215A patent/RS66117B1/sr unknown
- 2018-01-17 IL IL267894A patent/IL267894B2/en unknown
- 2018-01-17 EP EP18707848.0A patent/EP3571225B1/en active Active
- 2018-01-17 HR HRP20241469TT patent/HRP20241469T1/hr unknown
- 2018-01-17 CA CA3050575A patent/CA3050575A1/en active Pending
- 2018-01-17 SG SG10202108972RA patent/SG10202108972RA/en unknown
- 2018-01-17 EP EP24191393.8A patent/EP4442709A3/en active Pending
- 2018-01-17 FI FIEP18707848.0T patent/FI3571225T3/fi active
- 2018-01-17 IL IL312292A patent/IL312292A/en unknown
- 2018-01-17 LT LTEPPCT/EP2018/051083T patent/LT3571225T/lt unknown
- 2018-01-17 EP EP24191388.8A patent/EP4442707A3/en active Pending
- 2018-01-17 AU AU2018209151A patent/AU2018209151B2/en active Active
- 2018-01-17 US US16/477,918 patent/US11414481B2/en active Active
- 2018-01-17 MX MX2019008496A patent/MX2019008496A/es unknown
- 2018-01-17 KR KR1020247002265A patent/KR20240013861A/ko not_active Ceased
- 2018-01-17 PT PT187078480T patent/PT3571225T/pt unknown
- 2018-01-17 CN CN201880007313.6A patent/CN110191896B/zh active Active
- 2018-01-17 BR BR112019014599-0A patent/BR112019014599A2/pt unknown
- 2018-01-17 DK DK18707848.0T patent/DK3571225T3/da active
- 2018-01-17 SI SI201831169T patent/SI3571225T1/sl unknown
- 2018-01-17 HU HUE18707848A patent/HUE068790T2/hu unknown
2019
- 2019-07-16 MX MX2023005374A patent/MX2023005374A/es unknown
2022
- 2022-12-08 JP JP2022196232A patent/JP7628996B2/ja active Active
2024
- 2024-11-22 JP JP2024204085A patent/JP2025026992A/ja active Pending
2025
- 2025-05-13 AU AU2025203430A patent/AU2025203430A1/en active Pending

Also Published As

Publication number	Publication date
RS66117B1 (sr)	2024-11-29
AU2018209151B2 (en)	2025-02-27
AU2018209151A1 (en)	2019-07-25
US20190367597A1 (en)	2019-12-05
SI3571225T1 (sl)	2025-03-31
WO2018134235A8 (en)	2024-03-21
FI3571225T3 (fi)	2024-10-31
CN117285623A (zh)	2023-12-26
IL267894A (en)	2019-09-26
PT3571225T (pt)	2024-11-05
JP2025026992A (ja)	2025-02-26
IL267894B2 (en)	2024-10-01
IL312292A (en)	2024-06-01
EP4442709A3 (en)	2024-12-25
JP7219220B2 (ja)	2023-02-07
CN110191896A (zh)	2019-08-30
RU2019125831A3 (da)	2021-03-09
AU2025203430A1 (en)	2025-06-05
EP4442707A3 (en)	2024-12-25
EP3571225B1 (en)	2024-08-07
BR112019014599A2 (pt)	2020-03-03
US20230060574A1 (en)	2023-03-02
CA3050575A1 (en)	2018-07-26
KR20240013861A (ko)	2024-01-30
EP4442709A2 (en)	2024-10-09
KR102662499B1 (ko)	2024-05-02
WO2018134235A1 (en)	2018-07-26
HRP20241469T1 (hr)	2025-01-03
IL267894B1 (en)	2024-06-01
HUE068790T2 (hu)	2025-01-28
RU2019125831A (ru)	2021-02-19
JP7628996B2 (ja)	2025-02-12
ES2991459T3 (es)	2024-12-03
CN110191896B (zh)	2023-09-29
US11414481B2 (en)	2022-08-16
JP2023025232A (ja)	2023-02-21
EP4442707A2 (en)	2024-10-09
SG11201906264YA (en)	2019-08-27
EP3571225A1 (en)	2019-11-27
MX2023005374A (es)	2023-05-22
SG10202108972RA (en)	2021-09-29
JP2020515518A (ja)	2020-05-28
KR20190104608A (ko)	2019-09-10
LT3571225T (lt)	2024-11-11
MX2019008496A (es)	2019-09-18

Publication	Publication Date	Title
DK3571224T3 (da)	2024-11-11	Forbedrede serumalbuminbindere
IL267894A (en)	2019-09-26	Improved serum albumin binding agents
IL282960B (en)	2022-03-01	Serum albumin-binding fibronectin type iii domains
IL265321B1 (en)	2023-09-01	Cd3 binding antibodies
IL263840A (en)	2019-01-31	Cd3 binding antibodies
LT3374392T (lt)	2022-01-25	Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
DK3411065T3 (da)	2021-07-05	Clec9a-bindingsmidler
EP3621994A4 (en)	2020-12-30	MESOTHELIN BINDING PROTEINS
EP3481869A4 (en)	2020-02-26	ANTI-CD73 ANTIBODIES
DK3242892T3 (da)	2022-01-24	Modificerede april-bindende antistoffer
DK3464698T3 (da)	2022-07-25	Bindersystem
DK3529269T3 (da)	2026-02-23	Antistof-konstruktioner
EP3661961A4 (en)	2021-04-14	ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
IL272358B (en)	2022-02-01	Antigen-binding proteins that antagonize leptin receptor
DK3166970T3 (da)	2021-05-25	FORBEDREDE Aß-PROTOFIBRILBINDENDE ANTISTOFFER
DK3253785T3 (da)	2019-07-08	Hidtil ukendte egfr-bindingsproteiner
EP3579879A4 (en)	2020-12-16	ANTI-BODY ANTI-KIR3DL1
DK3484921T3 (da)	2022-02-07	Anti-IL-22R antistoffer
DK3452515T3 (da)	2025-11-17	Her-2-bindende antistoffer
DE112018000104A5 (de)	2019-05-29	Ablage
LT3456736T (lt)	2021-06-10	Antikūnų variantai
EP3881838A4 (en)	2022-08-17	ADHESIVE
EP3469003A4 (en)	2020-07-29	ANTI-PRL3 ANTIBODIES
EP3881839C0 (en)	2025-06-04	Bonding agent
DK3448420T3 (da)	2022-12-12	Anti-notch3-antistof